PMID- 23490191
OWN - NLM
STAT- MEDLINE
DCOM- 20130717
LR  - 20131121
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 155
IP  - 6
DP  - 2013 Jun
TI  - Intraocular concentrations of cytokines and chemokines in rhegmatogenous retinal 
      detachment and the effect of intravitreal triamcinolone acetonide.
PG  - 1028-1037.e1
LID - S0002-9394(13)00069-X [pii]
LID - 10.1016/j.ajo.2013.01.013 [doi]
AB  - PURPOSE: To investigate the role of intravitreal injection of triamcinolone 
      acetonide (IVTA) in preventing photoreceptor apoptosis in eyes with 
      rhegmatogenous retinal detachment (RRD) by measuring cytokine levels in the 
      aqueous humor before and after IVTA. DESIGN: Prospective, nonrandomized, 
      interventional case series. METHODS: setting: Institutional. patients: Nineteen 
      eyes of 19 consecutive patients with RRD. intervention: All 19 eyes underwent 
      IVTA 1 day before 25-gauge vitrectomy. Seventeen eyes free of retinal vascular 
      disease served as controls. main outcome measure: Both baseline and 1 day 
      post-IVTA measurements were made of the relative concentrations of 15 soluble 
      factors (3 cytokines, 7 chemokines, and 5 growth factors). The associations with 
      clinical findings, including macular status, were then analyzed. RESULTS: 
      Elevated monocyte chemotactic protein 1 (MCP-1), macrophage inflammatory protein 
      1beta (MIP-1beta), and interferon gamma-induced protein 10 (IP-10) in eyes with RRD were 
      significantly reduced after IVTA. MCP-1 levels were significantly correlated with 
      MIP-1beta and IP-10 before and after IVTA. The decreases in MCP-1, MIP-1beta, and IP-10 
      were also closely correlated to each other. Both before and after IVTA, MCP-1 was 
      higher in eyes with macula-off RRD than in eyes with macula-on RRD. CONCLUSIONS: 
      IVTA suppressed elevated levels of intraocular MCP-1, MIP-1beta, and IP-10 in eyes 
      with RRD. The decrease in the aqueous levels of each of these factors was 
      significantly correlated with the others. In addition to MCP-1, MIP-1beta and IP-10 
      might potentially be additional target molecules for RRD therapy.
CI  - Copyright (c) 2013 Elsevier Inc. All rights reserved.
FAU - Kunikata, Hiroshi
AU  - Kunikata H
AD  - Department of Ophthalmology, Tohoku University Graduate School of Medicine, 
      Sendai, Japan. kunikata@oph.med.tohoku.ac.jp
FAU - Yasuda, Masayuki
AU  - Yasuda M
FAU - Aizawa, Naoko
AU  - Aizawa N
FAU - Tanaka, Yuji
AU  - Tanaka Y
FAU - Abe, Toshiaki
AU  - Abe T
FAU - Nakazawa, Toru
AU  - Nakazawa T
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130312
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (CCL2 protein, human)
RN  - 0 (CCL4 protein, human)
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (Glucocorticoids)
RN  - F446C597KA (Triamcinolone Acetonide)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Chemokine CCL2/metabolism
MH  - Chemokine CCL4/metabolism
MH  - Chemokine CXCL10/metabolism
MH  - Chemokines/metabolism
MH  - Cytokines/*metabolism
MH  - Female
MH  - Glucocorticoids/*therapeutic use
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Retinal Detachment/*drug therapy/*metabolism
MH  - Triamcinolone Acetonide/*therapeutic use
MH  - Visual Acuity/physiology
MH  - Vitreous Body/*metabolism
EDAT- 2013/03/16 06:00
MHDA- 2013/07/19 06:00
CRDT- 2013/03/16 06:00
PHST- 2012/06/23 00:00 [received]
PHST- 2013/01/08 00:00 [revised]
PHST- 2013/01/08 00:00 [accepted]
PHST- 2013/03/16 06:00 [entrez]
PHST- 2013/03/16 06:00 [pubmed]
PHST- 2013/07/19 06:00 [medline]
AID - S0002-9394(13)00069-X [pii]
AID - 10.1016/j.ajo.2013.01.013 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2013 Jun;155(6):1028-1037.e1. doi: 10.1016/j.ajo.2013.01.013. 
      Epub 2013 Mar 12.